Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder

ClinicalTrials.gov ID: NCT00057239

Public ClinicalTrials.gov record NCT00057239. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy, Safety and Tolerability of Two Doses (20mg and 60mg) of a Once-Daily Oral Formulation of GW353162 in Subjects With Major Depressive Disorder for a Treatment Period of Eight Weeks

Study identification

NCT ID
NCT00057239
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
546 participants

Conditions and interventions

Interventions

  • Radafaxine Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 64 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2003
Primary completion
Apr 30, 2004
Completion
Apr 30, 2004
Last update posted
Oct 3, 2010

2003 – 2004

United States locations

U.S. sites
29
U.S. states
19
U.S. cities
28
Facility City State ZIP Site status
GSK Investigational Site Little Rock Arkansas 72223
GSK Investigational Site Newport Beach California 92660-2814
GSK Investigational Site Farmington Connecticut 6708
GSK Investigational Site Largo Florida 33773
GSK Investigational Site Maitland Florida 32751
GSK Investigational Site Miami Florida 33156
GSK Investigational Site North Miami Florida 33161
GSK Investigational Site Edwardsville Illinois 62025
GSK Investigational Site Glen Burnie Maryland 21061
GSK Investigational Site Farmington Hills Michigan 48336
GSK Investigational Site Minneapolis Minnesota 55454
GSK Investigational Site Clementon New Jersey 08021
GSK Investigational Site Kenilworth New Jersey 07033
GSK Investigational Site Lawrence New York 11559
GSK Investigational Site Charlotte North Carolina 28203
GSK Investigational Site Cleveland Ohio 44106
GSK Investigational Site Dayton Ohio 45408
GSK Investigational Site Oklahoma City Oklahoma 73118
GSK Investigational Site Eugene Oregon 97401
GSK Investigational Site Portland Oregon 97209
GSK Investigational Site Portland Oregon 97210
GSK Investigational Site Conshohocken Pennsylvania 19428
GSK Investigational Site Dallas Texas 75235
GSK Investigational Site Houston Texas 77004
GSK Investigational Site Irving Texas 75039
GSK Investigational Site Woodstock Vermont 05091
GSK Investigational Site Seattle Washington 98104
GSK Investigational Site Tacoma Washington 98499
GSK Investigational Site Brown Deer Wisconsin 53223

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00057239, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 3, 2010 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00057239 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →